Page 6 - M.Hofman-Session3
P. 6
LEARNING OBJECTIVES
By participating in this webinar, participants can expect to:
▪ Understand rationale combinations of 177 Lu-PSMA currently under
evaluation in clinical trials
▪ Discuss the possible mechanisms of resistance with 177 Lu-PSMA
▪ Review the role of alpha emitters including Radium-223
▪ Discuss if 177 Lu-PSMA should be used as an earlier line of treatment